Quick Answer
ADC Therapeutics SA reported Net Income Loss of -$142.62 million for the year ending 2025.
- ADC Therapeutics SA showed an increase of +9.6% in Net Income Loss from 2024 to 2025.
- This data is from ADC Therapeutics SA's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$59.37 million | Q2 2023: -$48.92 million | Q3 2023: -$46.73 million | Q1 2024: -$46.61 million | Q2 2024: -$36.54 million | Q3 2024: -$43.97 million | Q1 2025: -$38.60 million | Q2 2025: -$56.65 million | Q3 2025: -$40.97 million.
- Over the full 4 years of available data (2022 to 2025), ADC Therapeutics SA's Net Income Loss has grown by 9.2%.
- Historical annual values: Fiscal year 2025: -$142.62 million | Fiscal year 2024: -$157.85 million | Fiscal year 2023: -$240.05 million | Fiscal year 2022: -$157.13 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: